Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.57 |
| ▸ | KIT | P10721 | 5/20 | 0.57 |
| ▸ | BCR | P11274 | 10/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551463 | 1.00 | ABL1 (0.57) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL24250918 | 0.94 | ABL1 (0.62) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL29551241 | 0.94 | ABL1 (0.62) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL24250948 | 0.92 | PDGFRA (0.61) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL28709237 | 0.91 | ABL1 (0.61) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL29551443 | 0.91 | ABL1 (0.61) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL24251133 | 0.91 | PDGFRA (0.68) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL24251051 | 0.88 | PDGFRA (0.75) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL29552117 | 0.88 | PDGFRA (0.75) | ABL1PDGFRAKITBCRPDGFRB | |
| SCHEMBL24251073 | 0.87 | PDGFRA (0.62) | ABL1PDGFRAKITBCRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | ABL1 695/4885PDGFRA 145/4885KIT 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.